(Q37997942)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22456744%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

title

Role of chemotherapy in treatments for biliary tract cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22456744%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22456744%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

author name string

Junji Furuse

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22456744%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Atsuko Takasu

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22456744%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Hiroshi Kitamura

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22456744%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Fumio Nagashima

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22456744%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

publication date

1 July 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22456744%20AND%20SRC:MED&resulttype=core&format=json

Journal of Hepato-biliary-Pancreatic Sciences

27 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22456744%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

volume

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22456744%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22456744%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

page(s)

337-341

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22456744%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00534-011-0494-2

27 January 2020

exact match

0 references

cites work

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00534-011-0494-2

Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00534-011-0494-2

Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00534-011-0494-2

A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00534-011-0494-2

Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00534-011-0494-2

Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00534-011-0494-2

Lessons from the comparison of two randomized clinical trials using gemcitabine and cisplatin for advanced biliary tract cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00534-011-0494-2

S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00534-011-0494-2

Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00534-011-0494-2

Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00534-011-0494-2

Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00534-011-0494-2

Randomized phase II study of gemcitabine plus S-1 combination therapy vs. S-1 in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG0805).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00534-011-0494-2

Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00534-011-0494-2

Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00534-011-0494-2

10.1007/S00534-011-0494-2

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22456744%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

1 reference